<DOC>
	<DOCNO>NCT00474513</DOCNO>
	<brief_summary>GSK239512 develop treatment symptom cognitive impairment many disease . GSK239512 drug bind Histamine 3 receptor ( protein ) brain ( receptor occupancy ) . This study use technique positron emission tomography ( PET ) image tool highlight area brain GSK239512 penetrate , subsequently bound receptor , receive oral dose drug . It also look rate drug dissociate receptor brain . Results study provide information dose drug give study .</brief_summary>
	<brief_title>An Imaging Study Investigate Distribution GSK239512 Brain .</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Histamine H3 Antagonists</mesh_term>
	<criteria>Male age 35 49 inclusive screen visit . Healthy , define individual free clinically significant illness disease determine medical history ( include family history ) , physical examination , laboratory study , test judge investigator . Body weight â‰¥ 50 kg BMI within range 1929 kg/m2 , inclusive . Normal thyroid function test judge investigator . Willingness subject abstain sexual intercourse pregnant lactating woman ; willingness use adequate contraception time first dose [ 11C ] GSK189254 completion study 84 day follow study . Capable give informed consent comply study requirement timetable . The subject must able read , comprehend record information . A signed date write informed consent obtain subject prior take part study . The subject able understand comply protocol requirement , instruction protocolstated restriction . The subject must QTc &lt; 450msec ( male ) &lt; 480 msec subject bundle branch block The subject use use regular prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within fourteen day five half life ( whichever longer ) prior first dose study medication , unless opinion Investigator Sponsor medication would interfere study procedure compromise subject safety . Medications consider unlikely interfere study , thyroid replacement therapy , laxative , occasional use vitamin supplement , PRN paracetamol NSAIDs , prophylactic aspirin . The subject history drug alcohol abuse , positive prestudy urine drug / alcohol screen . Abuse alcohol define average weekly intake great 21 unit average daily intake great three unit male . One unit equivalent halfpint ( 220 mL ) beer one ( 25 mL ) measure spirit one glass ( 125 mL ) wine . History heavy use ( &gt; 10 per day ) tobacco nicotinecontaining product within six month start study . Heavy use caffeine ( &gt; 6 cup caffeinated beverage per day ) . The subject history presence drug significant allergy , opinion responsible physician , contraindicate participation . History presence neurological significant psychiatric disease , depressive disorder ( define HAD depression score &gt; 8 ) anxiety disorder ( define HAD anxiety score &gt; 8 ) See Appendix 7 . The subject history presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . The subject donate blood ( 450 mL ) within last three month study . The subject participate clinical study investigational non investigational drug device previous three month participate three study previous year . Previous inclusion research and/or medical protocol involve nuclear medicine , PET radiological investigation significant radiation burden , combination PET scan , may result subject receive 10mSv previous 3 year . History presence neurological psychiatric condition ( e.g. , stroke , traumatic brain injury , epilepsy , space occupy lesion , multiple sclerosis , Parkinson 's disease , vascular dementia , transient ischemic attack , schizophrenia , major depression etc ) may influence outcome analysis scan result compromise subject safety . Presence cardiac pacemaker electronic device ferromagnetic metal foreign body vulnerable position assess standard preMRI questionnaire . History know suspected seizure , unexplained significant loss consciousness history significant head trauma loss consciousness . Subjects febrile seizure childhood may include ceased age 5 type seizure medical history antiepileptic medication . Allen 's test result lead concern patency radial ulnar artery wrist use arterial cannulation . Needle phobia fear arterial blood sampling . A positive HIV1/2 , hepatitis B surface antigen positive hepatitis C antibody result within 3 month start study . Subjects QTc &gt; 500 msec . Subjects know history presence sleep disorder base investigator review medical history symptom</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AD , H3 , Brain , Cognitive Impairment</keyword>
</DOC>